Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Hyman, DM"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Teo, MY, Bambury, RM, Zabor, EC, Jordan, E, Al-Ahmadie, H, Boyd, ME, Bouvier, N, Mullane, SA, Cha, EK, Roper, N, Ostrovnaya, I, Hyman, DM, Bochner, BH, Arcila, ME, Solit, DB, Berger, MF, Bajorin, DF, Bellmunt, J, Iyer, G, Rosenberg, JE.
Publikováno v:
Urologic Oncology. Jul2018, Vol. 36 Issue 7, p345-346. 2p.
Autor:
Nancy Feeley, Juvianee Estrada-Veras, Filip Janku, Giulio Cavalli, Augusto Vaglio, Julien Haroche, Kenneth L. McClain, Lorenzo Dagna, Mark L. Heaney, Laurent Arnaud, Thomas V. Colby, David M. Hyman, Eli L. Diamond, Marina Ferrarini, Elisabetta Ferrero, Paul J. Scheel, Omar Abdel-Wahab
Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E mutations in >50% of patients, in which chronic uncontrolled inflammation is an important medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60c479987cce00473bb9befc763c52a
Autor:
Connolly RM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.; Cancer Research @UCC, College of Medicine and Health, University College Cork, Ireland., Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York., Grivas P; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington., Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hamilton SR; City of Hope National Medical Center, Duarte, California., Wang J; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas., Wisinski KB; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas., O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 01; Vol. 30 (7), pp. 1273-1280.
Autor:
Borazanci E; HonorHealth, Scottsdale, USA. Electronic address: eborazanci@honorhealth.com., Schram AM; Memorial Sloan Kettering Cancer Center, New York, USA., Garralda E; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Brana I; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Vieito Villar M; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Spreafico A; Princess Margaret Cancer Centre, Toronto, Canada., Oliva M; Princess Margaret Cancer Centre, Toronto, Canada., Lakhani NJ; START Midwest, Grand Rapids, USA., Hoffman K; Northern Biologics, Inc., Toronto, Canada., Hallett RM; Northern Biologics, Inc., Toronto, Canada., Maetzel D; Northern Biologics, Inc., Toronto, Canada., Hua F; Applied BioMath, Concord, USA., Hilbert J; Applied BioMath, Concord, USA., Giblin P; Northern Biologics, Inc., Toronto, Canada., Anido J; Northern Biologics, Inc., Toronto, Canada., Kelly A; Northern Biologics, Inc., Toronto, Canada., Vickers PJ; Northern Biologics, Inc., Toronto, Canada., Wasserman R; Northern Biologics, Inc., Toronto, Canada., Seoane J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona., Siu LL; Princess Margaret Cancer Centre, Toronto, Canada., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, USA., Hoff DV; HonorHealth, Scottsdale, USA., Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain.
Publikováno v:
ESMO open [ESMO Open] 2022 Aug; Vol. 7 (4), pp. 100530. Date of Electronic Publication: 2022 Jul 31.
Autor:
LeNoue-Newton ML; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Chen SC; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee., Stricker T; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York., Blauvelt N; Memorial Sloan Kettering Cancer Center, New York, New York., Bedard PL; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas., Punglia RS; Department of Radiation Oncology, DFCI, Harvard Medical School, Boston, Massachusetts., Schrag D; Division of Population Sciences and the Department of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts., Lepisto EM; Division of Population Sciences and the Department of Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts., Andre F; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France., Smyth L; Memorial Sloan Kettering Cancer Center, New York, New York., Dogan S; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France., Yu C; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Wathoo C; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas., Levy M; Departments of Biomedical Informatics and Medicine, Division of Hematology/Oncology, and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Eli LD; PUMA Biotechnology, Los Angeles, California., Xu F; PUMA Biotechnology, Los Angeles, California., Mann G; PUMA Biotechnology, Los Angeles, California., Lalani AS; PUMA Biotechnology, Los Angeles, California., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee., Micheel CM; Department of Medicine, Division of Hematology/Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Arnedos M; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; INSERM Unit, U981, Gustave Roussy Cancer Campus, Villejuif, France.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 May 13; Vol. 28 (10), pp. 2118-2130.
Autor:
Shrestha Bhattarai T; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shamu T; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gorelick AN; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chang MT; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology at Lilly, Stamford, CT, USA., Chakravarty D; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gavrila EI; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Donoghue MTA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gao J; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Patel S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gao SP; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reynolds MH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Phillips SM; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Soumerai T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Massachusetts General Hospital, Boston, MA, USA., Abida W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hyman DM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.; Loxo Oncology at Lilly, Stamford, CT, USA., Schram AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Solit DB; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Smyth LM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology at Lilly, Stamford, CT, USA., Taylor BS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Weill Cornell Medical College, New York, NY, USA. taylor.lab.msk@gmail.com.; Loxo Oncology at Lilly, Stamford, CT, USA. taylor.lab.msk@gmail.com.
Publikováno v:
Nature communications [Nat Commun] 2022 Apr 19; Vol. 13 (1), pp. 2111. Date of Electronic Publication: 2022 Apr 19.
Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Autor:
Rosen EY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Won HH; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology at Lilly, Stamford, CT, USA., Zheng Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cocco E; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; University of Miami, Miller School of Medicine, Department of Biochemistry and Molecular Biology/Sylvester Comprehensive Cancer Center, Miami, FL, USA., Selcuklu D; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gong Y; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Friedman ND; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Bruijn I; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sumer O; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bielski CM; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Savin C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bourque C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Falcon C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Clarke N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jing X; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Meng F; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zimel C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shifman S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kittane S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wu F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ebata K; Loxo Oncology at Lilly, Stamford, CT, USA., Kherani J; Loxo Oncology at Lilly, Stamford, CT, USA., Brandhuber BJ; Loxo Oncology at Lilly, Stamford, CT, USA., Fagin J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sherman EJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Berger MF; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Scaltriti M; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, Waltham, MA, USA., Hyman DM; Loxo Oncology at Lilly, Stamford, CT, USA., Taylor BS; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Weill Cornell Medical College, New York, NY, USA. taylor.lab.msk@gmail.com.; Loxo Oncology at Lilly, Stamford, CT, USA. taylor.lab.msk@gmail.com., Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. drilona@mskcc.org.
Publikováno v:
Nature communications [Nat Commun] 2022 Apr 05; Vol. 13 (1), pp. 1936. Date of Electronic Publication: 2022 Apr 05.
Autor:
Rosen EY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Won HH; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology at Lilly, Stamford, CT, USA., Zheng Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cocco E; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; University of Miami, Miller School of Medicine, Department of Biochemistry and Molecular Biology/Sylvester Comprehensive Cancer Center, Miami, FL, USA., Selcuklu D; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gong Y; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Friedman ND; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Bruijn I; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sumer O; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bielski CM; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Savin C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bourque C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Falcon C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Clarke N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jing X; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Meng F; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zimel C; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shifman S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kittane S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wu F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ebata K; Loxo Oncology at Lilly, Stamford, CT, USA., Kherani J; Loxo Oncology at Lilly, Stamford, CT, USA., Brandhuber BJ; Loxo Oncology at Lilly, Stamford, CT, USA., Fagin J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sherman EJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Berger MF; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Scaltriti M; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, Waltham, MA, USA., Hyman DM; Loxo Oncology at Lilly, Stamford, CT, USA., Taylor BS; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylor.lab.msk@gmail.com.; Weill Cornell Medical College, New York, NY, USA. taylor.lab.msk@gmail.com.; Loxo Oncology at Lilly, Stamford, CT, USA. taylor.lab.msk@gmail.com., Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. drilona@mskcc.org.
Publikováno v:
Nature communications [Nat Commun] 2022 Mar 18; Vol. 13 (1), pp. 1450. Date of Electronic Publication: 2022 Mar 18.